Literature DB >> 24740995

Obligate progression precedes lung adenocarcinoma dissemination.

Deborah R Caswell1, Chen-Hua Chuang2, Dian Yang1, Shin-Heng Chiou2, Shashank Cheemalavagu2, Caroline Kim-Kiselak3, Andrew Connolly4, Monte M Winslow5.   

Abstract

UNLABELLED: Despite its clinical importance, very little is known about the natural history and molecular underpinnings of lung cancer dissemination and metastasis. Here, we used a genetically engineered mouse model of metastatic lung adenocarcinoma in which cancer cells are fluorescently marked to determine whether dissemination is an inherent ability or a major acquired phenotype during lung adenocarcinoma metastasis. We find very little evidence for dissemination from oncogenic KRAS-driven hyperplasias or most adenocarcinomas. p53 loss is insufficient to drive dissemination but rather enables rare cancer cells in a small fraction of primary adenocarcinomas to gain alterations that drive dissemination. Molecular characterization of disseminated tumor cells indicates that downregulation of the transcription factor Nkx2-1 precedes dissemination. Finally, we show that metastatic primary tumors possess a highly proliferative subpopulation of cells with characteristics matching those of disseminating cells. We propose that dissemination is a major hurdle during the natural course of lung adenocarcinoma metastasis. SIGNIFICANCE: Because of its aggressively metastatic nature, lung cancer is the top cancer killer of both men and women in the United States. We show that, unlike in other cancer types, lung cancer dissemination is a major initial barrier to metastasis. Our findings provide insight into the effect of p53 deficiency and downregulation of Nkx2-1 during lung adenocarcinoma progression. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24740995      PMCID: PMC4090265          DOI: 10.1158/2159-8290.CD-13-0862

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  32 in total

1.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Authors:  G H Fisher; S L Wellen; D Klimstra; J M Lenczowski; J W Tichelaar; M J Lizak; J A Whitsett; A Koretsky; H E Varmus
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

2.  The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patients with lung cancer.

Authors:  J Buhr; K H Berghäuser; S Gonner; C Kelm; E A Burkhardt; W M Padberg
Journal:  J Thorac Cardiovasc Surg       Date:  1997-04       Impact factor: 5.209

3.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

4.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.

Authors:  S Rodenhuis; M L van de Wetering; W J Mooi; S G Evers; N van Zandwijk; J L Bos
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

5.  Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.

Authors:  T Berghmans; M Paesmans; C Mascaux; B Martin; A-P Meert; A Haller; J-J Lafitte; J-P Sculier
Journal:  Ann Oncol       Date:  2006-09-15       Impact factor: 32.976

6.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer.

Authors:  Julian A Schardt; Manfred Meyer; Claudia H Hartmann; Falk Schubert; Oleg Schmidt-Kittler; Christine Fuhrmann; Bernhard Polzer; Marco Petronio; Roland Eils; Christoph A Klein
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

7.  Combined transcriptome and genome analysis of single micrometastatic cells.

Authors:  Christoph A Klein; Stefan Seidl; Karina Petat-Dutter; Sonja Offner; Jochen B Geigl; Oleg Schmidt-Kittler; Nicole Wendler; Bernward Passlick; Rudolf M Huber; Günter Schlimok; Patrick A Baeuerle; Gert Riethmüller
Journal:  Nat Biotechnol       Date:  2002-04       Impact factor: 54.908

8.  Surgical treatment of non-small cell lung cancer 1 cm or less in diameter.

Authors:  Daniel L Miller; Charles M Rowland; Claude Deschamps; Mark S Allen; Victor F Trastek; Peter C Pairolero
Journal:  Ann Thorac Surg       Date:  2002-05       Impact factor: 4.330

9.  p53: a frequent target for genetic abnormalities in lung cancer.

Authors:  T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

10.  A genetic mouse model for metastatic lung cancer with gender differences in survival.

Authors:  S Zheng; A K El-Naggar; E S Kim; J M Kurie; G Lozano
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

View more
  25 in total

1.  Metastasis: shedding is no easy task.

Authors:  Gemma K Alderton
Journal:  Nat Rev Cancer       Date:  2014-06       Impact factor: 60.716

Review 2.  Deconstructing networks of p53-mediated tumor suppression in vivo.

Authors:  Alyssa M Kaiser; Laura D Attardi
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

3.  An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation.

Authors:  Christopher W Murray; Jennifer J Brady; Min K Tsai; Chuan Li; Ian P Winters; Rui Tang; Laura Andrejka; Rosanna K Ma; Christian A Kunder; Pauline Chu; Monte M Winslow
Journal:  Cancer Discov       Date:  2019-07-26       Impact factor: 39.397

4.  An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency.

Authors:  Jennifer J Brady; Chen-Hua Chuang; Peyton G Greenside; Zoë N Rogers; Christopher W Murray; Deborah R Caswell; Ursula Hartmann; Andrew J Connolly; E Alejandro Sweet-Cordero; Anshul Kundaje; Monte M Winslow
Journal:  Cancer Cell       Date:  2016-04-14       Impact factor: 31.743

5.  Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma.

Authors:  Lindsay M LaFave; Vinay K Kartha; Sai Ma; Kevin Meli; Isabella Del Priore; Caleb Lareau; Santiago Naranjo; Peter M K Westcott; Fabiana M Duarte; Venkat Sankar; Zachary Chiang; Alison Brack; Travis Law; Haley Hauck; Annalisa Okimoto; Aviv Regev; Jason D Buenrostro; Tyler Jacks
Journal:  Cancer Cell       Date:  2020-07-23       Impact factor: 31.743

6.  Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.

Authors:  Michelle Cicchini; Elizabeth L Buza; Kyra M Sagal; A Andrea Gudiel; Amy C Durham; David M Feldser
Journal:  Cell Rep       Date:  2017-02-21       Impact factor: 9.423

7.  Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.

Authors:  David M Walter; Olivia S Venancio; Elizabeth L Buza; John W Tobias; Charuhas Deshpande; A Andrea Gudiel; Caroline Kim-Kiselak; Michelle Cicchini; Travis J Yates; David M Feldser
Journal:  Cancer Res       Date:  2017-02-15       Impact factor: 12.701

8.  Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin.

Authors:  Dian Yang; Sarah K Denny; Peyton G Greenside; Andrea C Chaikovsky; Jennifer J Brady; Youcef Ouadah; Jeffrey M Granja; Nadine S Jahchan; Jing Shan Lim; Shirley Kwok; Christina S Kong; Anna S Berghoff; Anna Schmitt; H Christian Reinhardt; Kwon-Sik Park; Matthias Preusser; Anshul Kundaje; William J Greenleaf; Julien Sage; Monte M Winslow
Journal:  Cancer Discov       Date:  2018-09-18       Impact factor: 39.397

9.  Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1.

Authors:  Luca Lignitto; Sarah E LeBoeuf; Harrison Homer; Shaowen Jiang; Manor Askenazi; Triantafyllia R Karakousi; Harvey I Pass; Arjun J Bhutkar; Aristotelis Tsirigos; Beatrix Ueberheide; Volkan I Sayin; Thales Papagiannakopoulos; Michele Pagano
Journal:  Cell       Date:  2019-06-27       Impact factor: 41.582

Review 10.  Drivers of dynamic intratumor heterogeneity and phenotypic plasticity.

Authors:  Antara Biswas; Subhajyoti De
Journal:  Am J Physiol Cell Physiol       Date:  2021-03-03       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.